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Nine O-alkyl and O-prenyl derivatives were synthesized from commercial 2,4-dihydroxybenzophenone,
4,e4,40-dihydroxybenzophenone and were evaluated for their leishmanicidal activity against promasti-
gote forms of Leishmania amazonensis, as well their toxicity in murine macrophages. All derivatives exhib-
ited better biological activity than their hydroxylated benzophenones precursors, and new compound
LFQM-123 (3c) was 250-fold more active than its precursor 4,40-dihydroxybenzophenone (3). Moreover,
some of the results were comparable to the standard drug Amphotericin B, suggesting that the increase in
lipophilicity could facilitate protozoa membrane permeation. In this study we conﬁrmed that benzophe-
none derivatives exhibit leishmanicidal properties, with relatively low toxicity, and thus could be
exploited as promise prototypes for the design and development of new drug for the treatment of
leishmaniasis.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Leishmaniasis is a parasitosis transmitted by several species of
the protozoan genus Leishmania and is endemic in 88 tropical, sub-
tropical countries around the world. Recent rough estimates point
for a global prevalence of 12 million infected people and other 350
million at risk. This infectious disease is characterized by both
diversity and complexity, due to different clinical syndromes that
could be developed for more than 20 leishmanial species, transmit-
ted to humans by more than 30 different species of phlebotomine
sandﬂies.1 An important point to be considered is that in most of
cases, infected people live in countries with sanitary and fragile
governmental health systems, which are close related to the high
taxes of morbidity and mortality of the disease.
After transmission from the insect, all species of Leishmania
change from the ﬂagellar promastigote form to the amastigote
form and are internalized mainly in the macrophages. Then, they
can multiply and survive in the secondary phagolysosomes and
inﬁltrate to infect other surrounding macrophages.2 The diseaseoccurs in four main clinical forms: cutaneous leishmaniasis,
muco-cutaneous leishmaniasis, visceral leishmaniasis (VL) and dif-
fuse cutaneous leishmaniasis. Visceral leishmaniasis, also known
as kala-azar, is caused Leishmania donovani and L. infantum and is
the most serious infection form of the disease. In VL, the patient
generally presents symptoms of persistent infections, including fe-
ver, appetite and weight loss, hepatomegaly, hypergamaglobuline-
my, weakness, fatigue, and death if untreated2,3 Leishmania
brasiliensis is responsible for the most cases of muco-cutaneous
leishmaniasis, one of the most common clinical manifestation in
Brazil and other tropical countries. Leishmania amazonensis is a
member of the Leishmania Mexicana complex and the etiological
agent for a broad-spectrum of leishmaniasis in South American
countries.4 In Brazil, L. amazonensis infection can cause two distinct
clinical forms of cutaneous leishmaniasis: localized cutaneous
leishmaniasis and diffuse cutaneous leishmaniasis.5
Chemotherapy is the current basis for the treatment of leish-
maniasis, and effective anti-leishmanial vaccines are still under
study and development.6 Pentavalent antimonial drugs are the ﬁrst
choice treatment for leishmaniasis,2 and resistance arise is fre-
quently a problem in endemic areas. Amphotericin B and pentami-
dine are the second choice drugs, and have their therapeutic
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tion.2 In this context, and due to the restricted therapeutic alterna-
tives and high toxicity of the current medicines, the search in
biodiversity for new active compounds and extracts against Leish-
mania is a current ﬁeld in natural products and medicinal chemis-
try.6,7 In a recent communication, our group showed that natural
polyprenylated benzophenones like guttiferone-A, 7-epi-clusia-
none and garciniaphenone isolated from the fruits of Garcinia bra-
siliensis, exhibited leishmanial activity against amastigote and
promastigote forms of L. amazonensis, and 7-epi-clusianone was
the most active compound.8 In another work, Luque-Ortega
et al.,9 synthesized a series of benzophenone salts that revealed
that the presence of more lipophilic substituents clearly contribute
for the increase in leishmanicidal activity. In this work, we report
the synthesis of a series of methyl, butyl and prenyl-derivatives
of 2,4-dihydroxybenzophenone (1), 4-hydroxybenzophenone (2)
and 4,40-dihydroxybenzophenone (3) and their biological evalua-
tion against Leishmania and cytotoxicity.
2. Materials and methods
2.1. Experimental
The reactions were monitored by thin-layer chromatography
(TLC) performed on silica gel 60 F254 (Merck). Melting points
(in C) were determined using a Mettler melting point apparatus
(Mettler-Toledo, Leicester, UK) and are uncorrected. Chromatogra-
phy was performed on silica gel 60, 0.063–0.200 mm, (ACROS).
Elemental analysis was performed using a TruSPEC(CHN-S)
Analyzer by Leco Instruments. NMR spectrum was recorded on a
BRUKER Avance DPX 200 or BRUKER Avance DRX 400 spectrome-
ters. Chemical shifts are reported in parts per million (ppm) with
reference to tetramethylsilane (TMS). The coupling constants are
reported in hertz (Hz) and signal multiplicities are reported as
singlet (s), doublet (d), doublet of doublet (dd), mulitplet (m).
2.1.1. General procedure for conduction of O-alkylation
reactions
To a stirred solution of hydroxylated benzophenones
(1.0 mmol) in dimethylformamide/acetone (1:2 v/v) was added
potassium carbonate (2.0 equiv) and alkyl chloride or bromide
(1.5–3.0 equiv) at room temperature. The reaction mixture was
kept at 60 C monitored by TLC up to total consumption of starting
benzophenone. Then, reaction mixture was partitioned between
ethyl acetate and H2O, and the organic layers were combined, dried
over anhydrous Na2SO4, ﬁltered, and evaporated under reduced
pressure. The resulting crude residue was puriﬁed by silica gelTable 1
Chemical structures for benzophenone derivatives 1a–3c
O R1
R2R3
Alkylhalide,K2C
Acetone, DM
r.t.-60 C
1-3
Compound R1 R2 R3
LFQM-115 (1a) OH OH H
LFQM-116 (1b) OH OH H
LFQM-117 (1c) OH OH H
LFQM-118 (2a) H OH H
LFQM-119 (2b) H OH H
LFQM-120 (2c) H OH H
LFQM-121 (3a) H OH OH
LFQM-122 (3b) H OH OH
LFQM-123 (3c) H OH OHcolumn chromatography using hexane and ethyl acetate (8.5:1.5)
as eluent to give the alkylated benzophenone derivative (Table 1).
2.1.2. 2-Hydroxy-4-methoxybenzophenone10
Yellow crystalline solid. Mp 58 C; IR (KBr) tmax (cm1) 1256 (t
C–O–C); 1620 (t C@O); 2864 (t CH3). CG–MS m/z (%) 105(5);
77(14); 228(25); 31(100). 1H NMR (CDCl3; 200 MHz) d 3.8(s, 1H,
H-8); 6.3(d, 1H, H-3, J = 2.4 Hz); 6.4 (d, 1H, H-5, J = 2.4 Hz); 6.5
(t, 1H, H-6, J = 2.4 Hz); 7.5(t, 2H, H-30 and H-50 , J = 0.8 Hz); 7.6
(d, 2H, H-20 and H-60, J = 2.0 Hz). 13C NMR (CDCl3; 50 MHz) d 56.9
(C-3); 108.6 (C-5); 114.4 (C-1); 129.5 (C-20 and C-60); 130.1 (C-30
and C-50); 132.7 (C-40); 136.5 (C-10); 139.5 (C-60); 167.5 (C-2);
167.6 (C-4); 201.3 (C-7).
2.1.3. 2-Hydroxy-4-O-butylbenzophenone11 (LFQM-116, 1b)
Pale yellow crystalline solid. Mp 71 C; UV (EtOH; 0.1 %) kmax
(loge) 324 (0.24); 289 (0.15) and 243 (0.21) nm. IR (KBr) tmax
(cm1) 2800 (t C–H); 1624 (t C@O); 1266 (t C–O–C). CG–MS
m/z (%): 105 (5); 77 (14); 228 (25); 31(100). 1H NMR (CDCl3,
200 MHz) d 0.98 (t; 1H, H-11, J = 7.3 Hz); 1.4 (sex., 1H, H-10,
J = 7.2 Hz); 1.7 (q, 1H, H-9, J = 7.5 Hz); 4.0 (t, 1H, H-8, J = 6.5 Hz);
6.4 (d, 2H, H-3 and H-5, J = 2.2 Hz); 7.7 (d, 1H, H-6, J = 2.4 Hz);
7.5 (d, 2H, H-20 and H-60, J = 6.2 Hz); 7.7 (t, 1H, H-4, J = 4.0 Hz).
13C NMR (CDCl3; 50 MHz) d 16 (C-11); 17.4 (C-10); 21.8 (C-9);
70.7 (C-8); 96.8 (C-3); 102.7 (C-5); 113.9 (C-1); 130.1 (C-30;
C-50); 129.7 (C-20; C-60); 129.5 (C-6); 135.3 (C-10); 151.2 (C-2);
167.6 (C-4); 202.3 (C-7).
2.1.4. 2-Hydroxy-4-O-(3,3-dimethyl)-allylbenzophenone12
(LFQM-117, 1c)
White crystalline solid. Mp 88 C; UV (EtOH; 0.1 %) kmax (loge)
322 (0.25); 288 (1.70) and 243 (0.22) nm. IR (KBr) tmax (cm1)
2914 (t C–H); 1600 (t C@O); 1271 (t C–O–C). CG–MS m/z (%)
282 (1); 77 (5); 105 (5); 137 (6); 69 (50); 213 (60); 41 (100). 1H
NMR (CDCl3; 200 MHz) d 1.8 (s, 1H, H-11); 1.8 (s, 1H, H-12); 4.5
(d, 1H, H-8, J = 6.8 Hz); 5.4 (m, 1H, H-9); 6.4 (d, 1H, H-3,
J = 2.0 Hz); 6.5 (d, 1H, H-5, J = 2.4 Hz); 6.6 (d, 1H, H-6, J = 2,4 Hz);
7.5 (m, 1H, H-40); 7.6 (t, 2H, H-30 and H-50, J = 2.9 Hz); 7.7 (d, 2H,
H-20 and H-60, J = 1.6 Hz). 13C NMR (CDCl3; 50 MHz) d 18.9
(C-11); 23.0 (C-12); 66.1 (C-8); 120.1 (C-9); 141.9 (C-10); 104.3
(C-3); 105.7 (C-5); 110.7 (C-1); 129.1 (C-30 and C-50); 129.7
(C-6); 163.8 (C-4); 130.1 (C-20 and C-60); 133.4 (C-40); 137.4 (C-7).
2.1.5. 4-Methoxybenzophenone10 (LFQM-118, 2a)
Yellow crystalline solid. Mp 183 C; UV (EtOH; 0.1 %) kmax (loge)
416 (25); 288 (0.13), 252 (0.24); 224 (0.20); 204 (0.09) nm. IR (KBr)
tmax (cm1) 2968; 2935; 2845 (t C–H);1649 (t C@O); 1259O3
F
O R1
OR2'R 3'O
1a-3c
R02 R
0
3 Yield (%)
OCH3 H 51
O(CH2)3CH3 H 83
OCH2CHC(CH3)2 H 46
OCH3 H 48
O(CH2)3CH3 H 63
OCH2CHC(CH3)2 H 51
OCH3 OCH3 91
O(CH2)3CH3 O(CH2)3CH3 73
OCH2CHC(CH3)2 OCH2CHC(CH3)2 76
3116 C. M. Maciel-Rezende et al. / Bioorg. Med. Chem. 21 (2013) 3114–3119(t C–O–C). CG–MSm/z (%) 69 (50); 31 (90); 41 (100); 212 (100). 1H
NMR (CDCl3; 200 MHz) d 3.8 (s, 1H, H-8); 6.9 (d, 2H, H-3 and H-5,
J = 8.6 Hz); 7.4 (d, 2H, H-2 and H-6, J = 6.8 Hz); 7.5 (t, 2H, H-30 and
H-50, J = 6.5 Hz); 7.8 (t, 1H, H-40, J = 8.8 Hz). 13C NMR (CDCl3;
50 MHz) d 56.9 (C-8); 117.7 (C-3; C-5); 129.2 (C-2; C-6); 131.4
(C-2; C-6); 129.8 (C-20; C-60) 138.7 (C-40); 143.5 (C-10); 169.4
(C-4); 201.5 (C-7).
2.1.6. 4-Butoxybenzophenone11 (LFQM-119, 2b)
Pale yellow crystalline solid. Mp 65 C; UV (EtOH; 0.1 %) kmax
(loge) 416 (0.0005); 290 (0.09); 226 (0.09); 204 (0.2) nm. IR
(KBr) tmax (cm1) 2962; 2926 (t C–H); 1635 (t C@O); 1247 (t C–
O–C). CG–MS m/z (%): 77(30), 105(25), 121(100), 254(1). 1H NMR
(CDCl3; 200 MHz) d 1.0 (t, 1H, H-11, J = 7.3 Hz); 1.5 (sex, 1H,
H-10, J = 7.2 Hz); 1.7 (q, 1H, H-9, J = 8 Hz); 4.0 (t, 1H, H-8,
J = 6.5 Hz); 6.9 (d, 2H, H-3 and H-5, J = 8.8 Hz); 7.7 (d, 2H, H-2
and H-6, J = 2.4 Hz); 7.5 (d, 2H, H-20 and H-60, J = 7.4 Hz); 7.4
(t, 2H, H-30 and H-50, J = 7.1 Hz); 7.5 (t, 1H, H-40, J = 6.5 Hz). 13C
NMR (CDCl3; 50 MHz) d 14.3 (C-11); 20.4 (C-10); 32.4 (C-9); 66.9
(C-8); 115.2 (C-3; C-5); 129.4 (C-2; C-6); 130.9 (C-30; C-50); 132.8
(C-40); 133.6 (C-10); 166.4 (C-4); 195.5(C-7).
2.1.7. 4-O-(3,3-Dimethyl)-allylbenzophenone (LFQM-120, 2c)
White crystalline solid. Mp 179 C; UV (EtOH; 0.1 %) kmax (loge)
416 (0.0005); 290 (0.02); 250 (0.01) nm. IR (KBr) tmax (cm1)
2976; 2943(t C–H); 1598 (t C@O); 1255 (t C–O–C). CG–MS
m/z (%) 266 (1); 41(15); 105(20); 198(55); 121(65); 69(73). 1H
NMR (CDCl3; 50 MHz) d 1.7 (s, 2H, H-11 and H-12); 4.5 (d, 1H,
H-8, J = 6.8 Hz); 5.5 (t, 1H, H-9, J = 6.8 Hz); 6.9 (d, 2H, H-3 and H-
5, J = 8.8 Hz); 7.4 (d, 2H, H-2 and H-6, J = 7.2 Hz); 7.5 (d, 2H, H-20
and H-60, J = 7.2 Hz); 7.5 (d, 2H, H-3 and H-5, J = 7.2 Hz); 7.7
(t, 1H, H-40, J = 3.3 Hz). 13C NMR (CDCl3; 50 MHz) d 19.5 (C-11);
27.1 (C-12); 66.3 (C-8); 120.2 (C-9); 139.1 (C-10); 115.5 (C-3;
C-5); 129.4 (C-2; C-6); 133.0 (C-1); 131.2 (C-20; C-6); 133.1
(C-40); 163.8 (C-4); 195.9 (C-7).
2.1.8. 4,40-Di-methoxybenzophenone10 (LFQM-121, 3a)
Yellow crystalline solid. Mp 68 C; IR (KBr) tmax (cm1) 2924
(t C–H); 1637 (t C@O); 1253 (t C–O–C). CG–MS m/z (%): 242 (1);
77 (10); 135 (25); 31 (100). 1H NMR (CDCl3; 200 MHz) d 3.8
(s, 2H, H-8 and H-80); 6.9 (d, 4H, H-3 and H-5, H-30 and H-50
J = 8.8 Hz); 7.8 (d, 4H, H-2 and H-6, H-20 and H-60, J = 8.8 Hz). 13C
NMR (CDCl3; 50 MHz) d 56.7 (C-11); 114.4 (C-3; C-5;C-30; C-50);
131.7 (C-2; C-6; C-20; C-60); 133.4 (C-4; C-40); 195.7 (C-7).
2.1.9. 4,40-Di-butoxybenzophenone11 (LFQM-122, 3b)
Pale yellow crystalline solid. Mp 151 C; IR (KBr) tmax (cm1)
2933 (t C–H); 1637 (t C@O); 1249 (t C–O–C). 1H NMR (CDCl3;
200 MHz) d 0.9 (t, 2H, H-1 and H-110, J = 7.3 Hz); 1.4 (sex, 2H,
H-10 and H-100, J =7.3 Hz); 1.8 (q, 2H, H-9 and H-90, J = 7.2 Hz);
4.0 (t, 2H, H-8 and H-80, J = 6.4 Hz); 6.9 (d, 4H, H-3 and H-5, H-30
and H-50, J = 8.8 Hz); 7.0 (d, 4H, H-2 and H-6, H-20 and H-60,
J = 8.8 Hz). 13C NMR (CDCl3; 50 MHz) d 14.6 (C-11 e C-110); 19.9
(C-10 e C-100); 31.4 (C-9 e C-90); 68.7 (C-8 e C-80); 114.6 (C-3;
C-5; C-30; C-50); 131.3 (C-2; C-6; C-20 and C-60); 132.9 (C-1 e
C-10); 163.2 (C-4 and C-40); 195.2 (C-7).
2.1.10. 4,40-Di-O-(3,3-dimethyl)-allylbenzophenone12 (LFQM-
123, 3c)
White crystalline solid. Mp 99 C. IR (KBr) tmax (cm1) 2933
(t C–H); 1637 (t C@O); 1249 (t C–O–C). Anal. C 78.91%, H 7.46%,
calcd for C23H26O3, C 78.83%, H 7.48%. 1H NMR (CDCl3; 200 MHz)
d 1.7 (s, 4H, H-11 and H-110, H-12 and H-120); 4.5 (d, 2H, H-8
and H-80, J = 6.8 Hz); 5.5 (t, 2H, H-9 and H-90, J = 6.5 Hz); 6.9
(d, 4H, H-3 and H-5, H-30 and H-50, J = 8.8 Hz); 7.7 (d, 4H, H-2
and H-20, H-6 and H-60, J = 8.8 Hz). 13C NMR (CDCl3; 50 MHz) d18.8 (C-11; C-110); 26.4 (C-12; C-120); 65.5 (C-8; C-80); 119.6
(C-9; C-90); 139.3 (C-10; C-100); 114.6 (C-3; C-5 and C-30; C-50);
131.2 (C-2; C-6; C-20 and C-60); 132.7 (C-1; C-10); 162.7 (C-4;
C-40); 195.0 (C-7). The conﬁrmation of assignments was made by
2D-NMR experiments at 400 MHz (Supplementary data). This
compound is ﬁrst time described in the literature.2.2. Biological evaluation
2.2.1. Culture of Leishmania and in vitro assay
Promastigote forms of L. amazonensis (MHOM/BR/71973/
M2269) were grown on a 24-wells plate in Schneider’s Drosophila
medium (Sigma, USA) supplemented with 10.0% (v/v) heat-inacti-
vated fetal bovine serum and 1.0% penicillin (10,000 UI/mL)/strep-
tomycin (10.0 mg/mL) (Sigma, USA). Cells were harvested in the
log phase, re-suspended in fresh medium, counted in Neubauer’s
chamber and adjusted to a concentration of 1  106 cells/mL. Com-
pounds 1–3 and 1a–3c were added to promastigote cultures, at
1  106 cells/mL, solubilized in dimethylsulfoxide (DMSO) (the
concentration used was 0.6%, v/v in all wells) and incubated at
25 C. After 72 h of incubation, the surviving parasites were
counted in a Neubauer’s chamber and compared with controls
and DMSO in a concentration of 0.6% v/v, for the determination
of 50.0% inhibitory growth concentration (IC50). All tests were per-
formed in triplicate and Amphotericin B (Eurofarma) was used as
the reference drug.
2.2.2. Evaluation of cytotoxicity
For the cytotoxicity assay a suspension of 8  105 cells/mL of
murine peritoneal macrophages, in RPMI 1640 medium, supple-
mented with 10.0% heat-inactivated fetal bovine serum and 1.0%
penicillin (10,000 UI/mL)/streptomycin (10 mg/mL) were added
to each well in 24-well plates, on the glass slides of 13 mm. The
plates were incubated in a 5.0% CO2 air mixture at 37 C to adhesion
of the cells. After 24 h, the non-adherent cells were removed by
washing with the RPMI 1640 medium. Thus, several concentra-
tions of compounds 1–3 and 1a–3c (in the range of 0.05–
160.0 lg/mL) were added to the wells containing the cells. All
target compounds were solubilized in DMSO at a ﬁnal concentra-
tion of 0.6% v/v and the plates were incubated for more 72 h. Then,
the non-adherent cells were removed by washing with the RPMI
1640 medium and 50.0 lL of the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was added to each well
at concentration of 5.0 mg/mL, followed by incubation for more
4 h, as described by Mossman.14 After this, the mediumwas retired
and 1 mL of DMSO was added to each well and it was homogenized
for 15 min. Next, the absorbance of each individual well, minus the
control value, was calculated in according to the next formula at
570 nm.
%inhibition ¼ ODcontrol  ODdrugs
ODcontrol  100
 
Each experiment was performed in triplicate, and the percent-
age of viable cells was calculated in relation to control cultures
in the medium with just DMSO at the concentration of 0.6% v/v.
2.3. Statistical analysis
The leishmanicidal activities of compounds were expressed as
the concentration that inhibits the growth of 50.0% of protozoan
form. Statistical analysis was performed using nonlinear regression
to obtain the values of IC50 and CC50 (cytotoxic concentration for
50.0% of macrophages), followed by variance analyses and Tukey’s
test. Differences were signiﬁcant when the p value was lower than
0.05.
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Lipophilicity values were estimated through theoretical deter-
mination of LogP (oct/wat) by using the XLOGP3 program.13 The
additive model implemented in XLOGP3 uses a total of 87 atom/
group types and two correction factors as descriptors. It is cali-
brated on a training set of 8199 organic compounds with reliable
logP data through a multivariate linear regression analysis. Calcu-
lated lipophilicity expressed by LogP (oct/wat) of compounds 1–3
and 1a–3c are showed on Table 2.
3. Results and discussion
Considering that there is no vaccine available to prevent leish-
maniasis, discovery of new effective and low toxic drugs for the
treatment this neglected disease is an urgent need.14 Despite nat-
ural and synthetic benzophenones are not commonly reported
for their leishmanicidal properties, in the last years some works
from literature have showed that many benzophenone-derivatives
could be interesting for the development of new anti-protozoan
agents.15 In our work, we could conﬁrm that benzophenone deriv-
atives 1a–3cwith one or two hydroxyl groups in positions C-4 and/
or C-40 on the benzophenone skeleton exhibit a marked inhibitory
activity against Leishmania, being more active than the starting
hydroxylated benzophenones 1–3, and with low toxicity.
Antiprotozoal activity of compounds 1–3 and 1a–3c were eval-
uated in vitro against promastigote forms, and also for cytotoxicityTable 2
Chemical structure, biological and LogP data for benzophenone derivatives 1–3 and 1a–3c
Compound Chemical structure
1
O OH
OH
LFQM-115 (1a)
O OH
OCH3
LFQM-116 (1b)
O OH
O(CH2)3CH3
LFQM-117 (1c)
O OH
O
2
O
OH
LFQM-118 (2a)
O
OCH3
LFQM-119 (2b)
O
O(CH2)3CH3
LFQM-120 (2c)
O
Oin macrophages. Biological data evidenced that methylation, butyl-
ation and prenylation on the hydroxyl groups in C-4 and/or C-40
position in the original hydroxybenzophenones 1–3 resulted in
more active and low toxic compounds, compared to their precur-
sors 1–3 (Table 2).
Among the twelve compounds tested, compound 1a showed to
be the most active one with an IC50 = 4.90 lg/mL, but also exhibiting
the highest toxicity (CC50 = 24.60 lg/mL), with comparable values of
potency and cytotoxicity to Amphotericin B (IC50 = 4.70 lg/mL;
CC50 = 25.00 lg/mL), despite the weaker activity when compared
to Pentamidine (IC50 = 0.44 lg/mL). Besides derivative 1a, com-
pounds 1c (IC50 = 7.05 lg/mL; CC50 = 140.00 lg/mL), 2a
(IC50 = 5.05 lg/mL; CC50 = 28.00 lg/mL) and 3c (IC50 = 5.94 lg/
mL; CC50 = 160.00 lg/mL) also showed signiﬁcant inhibitory prop-
erties against promastigote forms of L. amazonensis, with a rela-
tively high toxicity observed for 2a. Considering a security index
(SI), expressed by the ratio between cytotoxicity (CC50) and anti-
leishmanial potency (IC50), compound 3c exhibited the best biolog-
ical proﬁle, with a SI = 26.93, followed by compound 1c (SI = 19.86)
in comparison to all other benzophenone derivatives and to stan-
dard drugs Amphotericin B (SI = 5.32) and Pentamidine (SI = 8.68).
A comparative analysis of biological data set also showed that
molecular modiﬁcations led to more cytotoxic compounds, as
evidenced by almost all monoalkylated derivatives in comparison
to the starting hydroxybenzophenones 1 and 2. As shown in
Table 2, except for compound 1c (CC50 = 140.00 lg/mL), all other, compared to Amphotericin B and Pentamidine
IC50a (lg/mL) Cytotoxicityb Log Pc
29.00 ± 6.66 >160.00 3.46
4.90 ± 0.72⁄ 24.60 ± 1.94⁄⁄ 3.79
9.80 ± 1.83⁄ 40.60 ± 1.85⁄⁄ 5.04
7.05 ± 0.44⁄ 140.06 ± 2.80 5.29
40.92 ± 1.67 >160.00 3.07
5.05 ± 0.21⁄ 28.00 ± 2.08⁄⁄ 3.40
8.56 ± 0.18⁄ 28.90 ± 1.50⁄⁄ 4.60
7.82 ± 0.50⁄ 87.10 ± 2.52 4.73
(continued on next page)
Table 2 (continued)
Compound Chemical structure IC50a (lg/mL) Cytotoxicityb Log Pc
3
O
OHHO
121.36 ± 6.33 >160.00 2.71
LFQM-121 (3a)
O
OCH3H3CO
21.30 ± 0.70⁄ 116.20 ± 2.18⁄⁄ 3.57
LFQM-122 (3b)
O
O(CH2)3CH3H3C(H2C)O
23.80 ± 8.90⁄ >160.00 5.71
LFQM-123 (3c)
O
OO
5.94 ± 1.31⁄ >160 6.21
Amphotericin B 4.70 25.00 —
Pentamidine 0.44 3.82 —
Values marked with one asterisk means that the derivative differs statistically from their starting compound when p <0.05 by Tukey’s test.
Values marked with two asterisk means that the derivative differs statistically from their starting compound when p <0.05 by Tukey’s test.
a Anti-leishmanicidal activity against promastigote forms of L. amazonensis.
b Cytotoxicity against murine macrophages.
c Calculated lipophilicity expressed by LogP (oct/wat) by using XLOGP3 program version 3.0.1.
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toxicity, ranging from 1.8 to 6.5-fold toxic in macrophages when
alkyl substituents were introduced in C-4 position of benzophe-
nones 1 and 2. Probably this observation could be explained by
an increase in lipophilicity as a consequence of alkylation of hydro-
xyl groups, as evidenced by LogP values estimated by XLOGP3 pro-
gram (Table 2). An increase in lipophilicity could explain the
marked increase in leishmanicidal and cytotoxic activity by facili-
tate the passage of active molecules through the cell membrane
barrier. A close relation between lipophilicity and antioxidant
activity was also reported by Urzúa and co-workers16 when they
evaluated the antimicrobial activity of a series of spiro-benzofuran
derivatives. On the other hand, an increase in molecular volume
and lipophilicity seems to have a synergistic important role in cel-
lular selectivity as evidenced by di-alkylated compounds 3a–3c
that showed to be active against Leishmania with low cytotoxicity.
This observation was more evident for compound 3c, substituted
by two prenyl moieties at C-4 and C-40 position and with a
LogP = 6,21, that exhibited the best biological proﬁle, showingFigure 1. Comparative analysis between variation in LogP and anti-leishmanial
activity of compounds 1–3 and 1a–3c.the be 20-fold more potent than original benzophenone 3, against
promastigote forms of L. amazonensis, along with the lowest cyto-
toxicity. This compound also showed anti-leishmanial activity
comparable to Amphotericin B, despite of the weaker activity re-
lated to Pentamidine.
In our study it was evidenced that an increase in the size of side
chain substituents led to a proportional increase in lipophilicity
and anti-leishmanial potency, as showed in Figure 1.4. Conclusions
Nine alkylated-benzophenone derivatives (compounds 1a–3c)
were prepared in good chemical yields from commercial 2,4-dihy-
droxybenzophenone (1), 4-hydroxybenzophenone (2) and 4,40-
dihydroxybenzophenone (3). All synthetic derivatives 1a–3c
exhibited a remarkable inhibition of the growth of promastigote
forms of L. amazonensis with the highest anti-leishmanial activity
evidenced for compounds 1a, 1c, 2a and 3c. The most highlighted
results seems to be for compound 3c that showed the best relation-
ship between anti-leishmanial and cytotoxicity against macro-
phages, with represent a good indicative for therapeutic index for
the development of a new drug candidate prototype. In a compar-
ative analysis of all results, it was evidenced that variation in lipo-
philicity of the target molecules was an important requisite for
modulation of antileishmanial activity and toxic effects in macro-
phages. In early studies, Pereira and co-workers8 showed that
benzophenones with higher lipophilicity present highest activities
against Leishmania species, which could in fact be related to the
ease to come in the macrophage and to reach the parasite. In this
context, further studies should be conducted to better understand
the mechanism of action of these molecules and their effectiveness
against amastigote forms of Leishmania. For both, will be used com-
pounds with low cytotoxicity and increased activity in Leishmania
promastigotes forms. Thus, these series of benzophenone deriva-
tives could be explored as new drug prototype candidates to antile-
ishmanial agents with easy access from commercial starting
materials, good lead to new bioactive chemical entities with low
toxicity and good selectivity.
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